Lindus Health is set to partner with the Clinical Data Interchange Standards Consortium (CDISC) to leverage AI in accelerating the development of standardised biomedical concepts for clinical trials.
This collaboration aims to streamline the clinical trial data collection and analysis process worldwide.
Go deeper with GlobalData
According to the company, the traditional method of generating biomedical concepts is a complex and time-consuming process, requiring deep knowledge of clinical research standards, data modelling, and medical terminology.
Lindus Health’s AI technology aids in significantly expediting this process, allowing a larger number of biomedical concepts to be produced with increased ‘efficiency’.
Trial data that is submitted to regulatory bodies such as the US Food and Drug Administration (FDA) must comply with the standards of the CDISC.
The CDISC works with these agencies to enhance standards, ensuring data is structured and consistent for analysis and review.
The strategic initiative by CDISC to create ‘uniform’ terminology using biomedical concepts is expected to improve data sharing, analysis, and regulatory reviews, thereby accelerating medical innovation.
Its biomedical concepts are tailored to ensure data consistency, link information throughout the data pipeline, and facilitate data sharing across studies.
The application of large language models (LLMs) is claimed to simplify the creation of these concepts, enabling researchers to document and share data using standardised terminology.
This process is intended to work across all therapeutic areas, improving the speed of concept creation while maintaining data integrity.
Lindus Health co-founder Meri Beckwith said: “Our partnership with CDISC showcases our commitment to eliminating manual, slow processes in clinical research.
“We’re humbled to have the unique opportunity to improve data standards for the entire industry with AI, and we can’t wait to see what we accomplish together.”
Leveraging AI and other technologies, Lindus Health is focused on ‘optimising’ various aspects of clinical operations, including the development of protocols, trial design, and central monitoring, among others.
Last month, Lindus Health secured $55m in Series B funding to support its fully integrated, AI-powered research services.
